Screening and Detection of Ovarian Cancer

Journal of Midwifery and Women's Health - Tập 50 - Trang 51-54 - 2005
Ginger Breedlove, Cara Busenhart

Tóm tắt

According to the National Cancer Institute, ovarian cancer is the sixth most common cancer in women and the leading cause of death from gynecologic malignancies. Most often the disease is advanced before symptoms are evident. It is estimated that only 15% to 30% of women in advanced stages will survive 5 years, whereas, of women in stage I at the time of diagnosis, 95% are likely to be alive in 5 years, and most are cured following surgery. Current screening techniques recommended for women with known strong risk factors include combination transvaginal sonography with cancer antigen (CA‐125). Transvaginal sonography and serum CA‐125 have limited diagnostic predictability. A new early detection method that uses proteomic technology will soon be available. The OvaCheck test, as researchers purport, is a highly specific and sensitive early detection method for ovarian cancer in women with strong risk factors. The Food and Drug Administration has yet to approve nationwide marketing of OvaCheck for early detection, because trials are not yet complete. Anticipated commercial availability is scheduled for early 2005.

Tài liệu tham khảo

10.1097/00001622-200409000-00012 American Cancer Society.All about ovarian cancer. [citedSeptember 22 2004]. Available from:http:www.cancer.org. 10.1016/S0090-8258(03)00254-3 10.1016/S0140-6736(02)07746-2 10.1016/S0020-7292(00)90001-8 10.1677/erc.0.0110163 Pollack A., 2004, New test for ovarian cancer stirs hope and concern, The New York Times Correlogic Systems Inc. News release:Correlogic Systems' ovarian cancer blood test to advance through North‐Shore‐LIJ Research Institute research collaboration June 21 2004. GutmanS.Letter to Peter Levine President and CEO Correlogic Systems Inc.(July 12 2004). [cited September 29 2004]. Available from:http:www.fda.govcdrhoivdletters071204‐correlogic.html. LevineP.Letter to Steven Gutman Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health. [citedSeptember 29 2004]. Available from:http:www.correlogic.comJuly14SteveGutmanLetter.pdf. 10.1038/429496a Society of Gynecologic Oncologists.Society of Gynecologic Oncologists Statement Regarding OvaCheck February 7 2004. Available from:http:www.sgo.orgpolicyposition_Statement.cfm. 10.1093/jnci/96.7.500 Sorace JM, A data review and re‐assessment of ovarian cancer serum proteomic profiling, BMC Bioinformatics, 4 U.S. Preventive Services Task Force.Screening for ovarian cancer: Brief evidence update. Posted May 2004. Agency for Healthcare Research and Quality Rockville MD. [citedOctober 5 2004]. Available from:http:www.ahrq.govclinic3rduspstfovariancanovcanup.htm. National Cancer Institute (NCI) News Center.Questions and Answers: Proteomics and cancer. Posted April 30 2004. [cited October 1 2004]. Available from:http:www.cancer.govnewscenterpressreleasesproteomicsQandA.
Thông tin
Thông tin xuất bản

Journal of Midwifery and Women's Health

Tập 50

51-54

Thông tin tác giả